Lutetium (177 Lu) Vipivotide Tetraxetan

The radioligand field is on the cusp of a major competitive moment, as a rival looks to bring the first generic to a market that’s been dominated by Novartis. Radioligand therapy aims to bring the cell-damaging effects of radiation directly to the tumor site while minimizing damage to surrounding healthy cells. Novartis compares the drugs to a “smart key” that only delivers a radioactive payload once it fits into a “lock” found on cancer cells. Over the last decade, Novartis has turned radioligand therapy into a multibillion-dollar franchise. It hasn’t been easy: The drugs’ short half-lives, complex manufacturing process, and supply chain requirements make them challenging to effectively produce and distribute. But what was once a niche field has gained momentum with more than 400 clinical trials registered , and other major pharma companies have made significant investments . Now, a generic manufacturer is looking to enter the arena — testing whether it can bring a lower-cost product to one of the industry’s most complex manufacturing and supply chain processes. Lantheus’ “radioequivalent” version of Novartis’ drug Lutathera, PNT2003, won tentative approval last month to treat certain gastroenteropancreatic neuroendocrine tumors, also known as GEP-NETs. Amid a legal challenge by Novartis, Lantheus said a full approval is contingent upon the end of a 30-month stay this summer. If fully approved, Lantheus’ drug would be the first generic alternative to Lutathera, which generated $816 million in 2025 sales and has a list price of about $67,000 per infusion. Lantheus executives have touted a “sizable market” to address. But industry experts say Novartis would remain a formidable competitor, in part because of its growing manufacturing and distribution network. “One thing this area does come with is a bit of a moat,” Jefferies analyst Michael Leuchten said. “Which for large pharma companies is important these days, given that we’re heading into a very, very big patent cliff for the industry by 2030.” Lantheus declined a request to speak for this article. Novartis has called the radioligand field a $28 billion market opportunity. Its treatments Lutathera and Pluvicto, the latter of which is approved for prostate cancer, together brought in roughly $2.8 billion in 2025 sales. Novartis has also rapidly expanded its manufacturing network to meet demand, after facing supply issues. In 2022, the company paused delivery of Lutathera and Pluvicto in the US “out of an abundance of caution” to address potential quality issues at certain manufacturing sites. The company resumed production at those sites the following month, and announced plans to ramp up its production capabilities. A drug shortage on Pluvicto was resolved the following year, and Novartis has laid out plans for a network of five manufacturing sites in the US, the fifth of which was announced in February. Lantheus’ Lutathera generic could be a “reasonable test case” for launching a radiosimilar before Novartis’ bigger product Pluvicto can be referenced, said Cody Powers, principal at the consulting firm ZS. But the test isn’t just manufacturing and distributing the drug — it’s also convincing patients you can deliver treatments on time. Radioligands are produced for each individual patient. Radioisotopes are formed in a nuclear reactor, then bonded to a ligand that directs the therapy to the target cancer cells. The finished radioactive product decays quickly, putting pressure on how fast it must be delivered. Novartis packs the material into a lime green, lead-shielded canister, transports it under strict temperature and safety controls, and delivers it to the patient within days. “The way I like to think about it is like shipping an ice cream across the country in summer,” Novartis’ US president Victor Bulto said. “The entire manufacturing and distribution process hinges around the fact that this is a just-in-time, patient-by-patient manufacturing.” Novartis says it has a 99.5% on-time shipping rate. Pluvicto must be infused within five days of being manufactured and Lutathera needs to be administered within 72 hours. Last April, CEO Vas Narasimhan questioned on an earnings call whether a potential generic maker can “produce the medicine in a way that doesn’t also infringe on our patents in terms of production and know-how in terms of production,” and deliver on time. “Everything has to be precisely timed to be able to execute this successfully,” Powers said. “You still have to ensure super reliable supply if you’re cutting the price.” Jefferies’ Leuchten said a radiosimilar isn’t likely to move the needle much on pricing, at least not at first. He compared the dynamics to the first biosimilars, which “priced at a discount, but not a significant discount.” For instance, when Novartis launched the first biosimilar in 2015, it came in at a price 15% below its brand-name competitor. Since then, dozens of biosimilars have been approved and their prices average closer to a 50% discount. “I don’t see any reason why they wouldn’t be able to compete,” Leuchten said of Lantheus and its generic, but added that “I do think that will take some time.” He added that it could become a duopoly, where “a race to the bottom on pricing” isn’t likely to occur. Meanwhile, Novartis’ capacity to source radioactive material and deliver its drugs in a timely manner could allow the company to keep its edge on the radioligand market, even in the absence of key patents. Lantheus appears to be shoring up its manufacturing footprint. The company completed a $1 billion acquisition of Evergreen Theragnostics last year, giving it access to “scalable manufacturing capabilities and infrastructure.” The company also gained a diagnostic agent that it said would be “complementary” to its Lutathera radiosimilar. The company has said it would leverage its existing supply network if PNT2003 wins full approval. Chief commercial officer Amanda Morgan said on an earnings call in February that the Lutathera generic would be a “natural addition to the Lantheus commercial portfolio of products.” Interim CEO Mary Anne Heino projected that confidence at a TD Cowen conference in March. “This fits squarely in our sweet spot,” she said, according to an AlphaSense transcript. Meanwhile, a Delaware federal judge continues to mull Novartis’ patent infringement claims in a case against Lantheus. Novartis has asked the court to block Lantheus from launching its generic until key patents expire, while Lantheus has argued that the disputed patent claims are invalid. A bench trial occurred in December, but a verdict has not been reached. Novartis declined to comment on the lawsuit. The company is also involved in a lawsuit against Curium Pharma, which submitted an application in 2024 to market its own version of Lutetium Lu 177 Dotatate, the active ingredient in Lutathera. The Lantheus and Curium cases were consolidated last year. The outcome will determine what happens in June — and how quickly a competition will brew. Editor’s note: This story has been updated to clarify that Lutathera is administered as an infusion. Endpoints is fielding the next Biopharma Sentiment Index (BPSI) — a concise, three-minute survey that distills thousands of industry views into a clear quarterly benchmark. This year is pivotal for biopharma, and we need your perspective on where things are going. Take the survey here.

Advanced Urology opens the Atlanta Prostate Center — focal ablation, robotic prostatectomy, brachytherapy, and Pluvicto infusion under one roof. ATLANTA, GA, UNITED STATES, April 22, 2026 / EINPresswire.com / -- Advanced Urology today announced the opening of the Atlanta Prostate Center, a new comprehensive program designed to deliver the full continuum of modern prostate cancer care — from earliest-stage focal therapy through advanced metastatic treatment — under a single coordinated clinical model. Prostate cancer is the second most commonly diagnosed cancer in American men, and the treatment landscape has changed dramatically over the past decade. Patients now have options ranging from active surveillance to focal ablation, brachytherapy, robotic surgery, and — for men with advanced disease — newly approved targeted and immunotherapy agents that were not available even a few years ago. Matching the right treatment to the right patient requires access to every modality, evaluated by a team experienced in all of them. The Atlanta Prostate Center is built to be that destination. "Prostate cancer is no longer a one-treatment disease," said Jitesh Patel, MD, Founder and President of Advanced Urology. "Men deserve a center where every modern option is available, where the treatment decision is driven by the disease and the patient rather than by what a particular practice happens to offer, and where the latest technology is delivered in modern, patient-friendly settings. That is what the Atlanta Prostate Center is built to be." The Full Continuum of Modern Prostate Cancer Care The Atlanta Prostate Center consolidates the following treatment modalities under one program: Focal ablation with Vanquish . For appropriately selected men with localized prostate cancer, focal ablation treats only the cancerous portion of the gland while preserving the remainder — an approach designed to control the cancer while protecting continence and sexual function. The center uses the Vanquish platform, one of the most advanced focal ablation technologies available, delivered in an outpatient setting. Brachytherapy. For patients for whom radiation-based treatment is the optimal choice, the center offers modern brachytherapy — the implantation of radioactive seeds directly into the prostate — performed in Advanced Urology's state-of-the-art ambulatory surgery centers. Brachytherapy delivers highly targeted radiation to the prostate while minimizing exposure to surrounding tissue. Robotic prostatectomy with the da Vinci robot. For patients who require or prefer surgical removal of the prostate, robotic-assisted radical prostatectomy is performed at Advanced Urology's Center for Special Surgery in Alpharetta. The center is equipped with the latest da Vinci robotic platform, and Advanced Urology's surgeons have extensive experience delivering robotic prostatectomy — including in an outpatient setting — with a focus on oncologic control, continence preservation, and potency preservation. Advanced drug therapy and infusion. For men with advanced or metastatic prostate cancer, the center offers access to the latest FDA-approved systemic therapies, including Pluvicto (lutetium Lu 177 vipivotide tetraxetan), a targeted radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer, and Provenge (sipuleucel-T), an autologous cellular immunotherapy for select patients with metastatic castration-resistant disease. These therapies, which have historically required patients to travel to academic cancer centers, are available through the Atlanta Prostate Center in a community-based outpatient setting. Modern Infrastructure Across Multiple Sites The Atlanta Prostate Center operates across Advanced Urology's statewide clinical infrastructure, allowing each treatment to be delivered in the setting best suited to it: The Center for Special Surgery in Alpharetta, Advanced Urology's flagship surgical facility, equipped with the latest da Vinci robotic platform for prostatectomy and other advanced procedures Advanced Urology's network of ambulatory surgery centers across Georgia, equipped for focal ablation, brachytherapy, biopsy, and related procedures, with same-day discharge Dedicated infusion capability for advanced drug therapy, including Pluvicto and Provenge administration, delivered in a patient-friendly outpatient environment Integrated diagnostic and imaging capability, including advanced prostate imaging and PSMA-based staging to guide treatment selection This infrastructure allows the center to deliver hospital-grade oncologic care in settings designed around patient convenience, shorter recovery, and lower overall cost of care. A Coordinated Model for a Complex Disease "The biggest challenge for men diagnosed with prostate cancer is not just choosing a treatment — it is understanding which treatment is right for their specific disease, and having access to it without bouncing between institutions," said Vahan Kassabian, MD, Chief Physician Officer of Advanced Urology. "The Atlanta Prostate Center is designed so that every option is on the table from day one, every modality is delivered by physicians who specialize in it, and every patient is supported by a coordinated team from diagnosis through survivorship or advanced care." Serving Patients Across Georgia The Atlanta Prostate Center is now accepting new patients and referrals from primary care physicians, medical oncologists, and other specialists across the region. Consultations and second opinions can be scheduled by calling 678-344-8900 or visiting advancedurology.com. About Advanced Urology Advanced Urology is metro Atlanta's most innovative urology practice, with 14 clinic locations and 6 ambulatory surgery centers across Georgia, including the Center for Special Surgery in Alpharetta. The practice provides comprehensive urologic care for men and women, with specialized programs in prostate cancer, kidney stones, recurrent UTI, BPH, overactive bladder, low testosterone, and erectile dysfunction. To learn more, visit advancedurology.com or call 678-344-8900. Jitesh Patel Advanced Urology email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.